TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24456143
Drug: Post-fatigue laser
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-fatigue laser treatment
Study: 24456143
Drug: Pre-fatigue laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-fatigue laser treatment
Study: 21134997
Drug: Varenicline 1
Normalized name: varenicline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily for 12 weeks
Study: 6893692
Drug: Molsidomine (M)
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (M) 4 mg, single dose
Study: 6893692
Drug: Molsidomine (M),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (M), prolonged treatment
Study: 6893692
Drug: Molsidomine (M),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (M), single dose
Study: 30921748
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive therapies
Study: 26844926
Drug: Inhaled allergen
Normalized name: Inhaled allergen mix specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled allergen
Study: 27886976
Drug: Inhaled diesel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled diesel exhaust (DE) and allergen co-exposure
Study: 14981009
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (1.5 pmol/kg per minute) for 72 hours
Study: 11316375
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg + Relapse Prevention Therapy (RP)
Study: 11316375
Drug: Naltrexone 0
Normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 0 mg + Relapse Prevention Therapy (RP)
Study: 11316375
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg + Drug Counseling
Study: 11316375
Drug: Naltrexone 0
Normalized name: MORPHINE 20MG/NALTREXONE 0.8MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 0 mg + Drug Counseling
Study: 10638409
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg MDE
Study: 2658525
Drug: Penbutolol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 10 mg/day
Study: 2658525
Drug: Penbutolol 20
Normalized name: penbutolol 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 20 mg/day
Study: 2658525
Drug: Penbutolol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol 40 mg/day
Study: 901695
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg metoprolol tartrate
Study: 901695
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg metoprolol tartrate
Study: 31025258
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of rocuronium 0.6 mg·kg−1·hr−1
Study: 29178954
Drug: Colloidal silver
Normalized name: COLLOIDAL SILVER
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal silver (CS) nasal spray, administered twice daily for six weeks
Study: 29178954
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray, administered twice daily for six weeks
Study: 25467016
Drug: Lapatinib (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1000 mg orally daily)
Study: 25467016
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly)
Study: 25467016
Drug: Trastuzumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab + Lapatinib (at the same doses)
Study: 21153021
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg infused once yearly
Study: 18294736
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) added to approved AD therapies for 6 months, then discontinued, and resumed for another 9 months
Study: 18028126
Drug: Topical recombinant
Normalized name: thrombin topical recombinant 5000 intl units topical powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical recombinant human acidic fibroblast growth factor (rh‐aFGF)
Study: 11772241
Drug: Aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminolevulinic acid (ALA) in photodynamic therapy (PDT)
Study: 11772241
Drug: ALA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA treatment for non-tumoural applications
Study: 7909853
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate (42 micrograms inhaled twice daily)
Study: 7909853
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 micrograms inhaled four times daily)
Study: 30098961
Drug: 400/200 eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g
Study: 30098961
Drug: Almost pure
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almost pure EPA at 2 g
Study: 26556736
Drug: MK-5442 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5442 (5, 7.5, 10, or 15 mg daily)
Study: 26556736
Drug: MK-5442 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5442 (10 mg)
Study: 26556736
Drug: ALN 70
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN 70 mg weekly
Study: 25662545
Drug: Glucosamine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (1500 mg) and Chondroitin (1200 mg) combination
Study: 25662545
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCl (50 mg, twice daily)
Study: 20669577
Drug: Needle warming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle warming therapy
Study: 31567988
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment
Study: 20669577
Drug: Body acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body acupuncture treatment
Study: 14616152
Drug: Rabeprazole (RB)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RB) 20 mg/d in the evening (p.m.)
Study: 14616152
Drug: Rabeprazole (RB)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RB) 20 mg/d in the morning (a.m.)
Study: 11062356
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 500 mg calcium supplement
Study: 8629588
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg/day orally)
Study: 10910491
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg meperidine
Study: 1599888
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg bupivacaine
Study: 1599888
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg meperidine plus 12.5 mg bupivacaine
Study: 1599888
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bupivacaine
Study: 1599888
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg bupivacaine
Study: 29792370
Drug: belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: belimumab 10 mg/kg plus standard of care (SoC)
Study: 22440488
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg, 3 times daily, starting 6 hours before ascent
Study: 19341510
Drug: Sertraline (flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (flexible dosages up to 200 mg/d)
Study: 19341510
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group therapy (one individual session and nine group sessions per 90 min)
Study: 19341510
Drug: Patients' choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' choice arm (sertraline or cognitive-behavioural group therapy)
Study: 17493418
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d)
Study: 11154053
Drug: Sheng-ji-san (SJS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sheng-ji-san (SJS) treatment combined with routine medical care
Study: 6149535
Drug: Almitrine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (1.5 mg/kg orally)
Study: 29618098
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTi)
Study: 30095981
Drug: Bimagrumab 30
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 30 mg/kg intravenously
Study: 26978497
Drug: Nonspecific cytoprotective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific cytoprotective therapy (cytoflavin)
Study: 15169706
Drug: Risperidone treatment
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone treatment for 6 months
Study: 21782166
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day for 5 days
Study: 21782166
Drug: Raloxifene (R)
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene (R) 100 mg/day for 5 days
Study: 17570206
Drug: Combination antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antibiotic therapy (clarithromycin 750 mg/day, rifabutin 450 mg/day, clofazimine 50 mg/day)
Study: 9356530
Drug: Combined dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dose of beta-carotene and canthaxanthin
Study: 7524457
Drug: Topical aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical aprotinin (50 mL; 70 mg)
Study: 3036335
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs and drug combinations for recurrent Wilms' tumor
Study: 3036335
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for localized embryonal rhabdomyosarcoma
Study: 3036335
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for tumors of the prostate, bladder neck, or trigone
Study: 3036335
Drug: Platinum-containing combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-containing combination chemotherapy regimens for advanced yolk sac tumor
Study: 3036335
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug combinations in locally advanced tumors
Study: 3036335
Drug: Etoposide-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide-containing combination chemotherapy regimens
Study: 29358433
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + prescribed fluid intake
Study: 29358433
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + usual fluid intake
Study: 12434259
Drug: 200 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/70 kg oral caffeine t.i.d. (caffeine maintenance)
Study: 15010695
Drug: Intravenous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine (1.0 and 2.0 mg/70 kg)
Study: 15010695
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine (200 and 400 mg/70 kg)
Study: 3513529
Drug: Guanfacine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (1 mg/day, adjustable to max 3 mg/day)
Study: 28298187
Drug: internet-delivered transdiagnostic
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Study: 26181090
Drug: Family planning
Normalized name: Lubricant Topical application Gel/Jelly [FAMILY PLANNING LIQUID LUBRICANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family planning services (counseling, prescription or procedure related to birth control)
Study: 12804986
Drug: Calcitriol 3
Normalized name: CALCITRIOL 3MCG/GM OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 3 mug/g ointment
Study: 12804986
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 mug/g ointment
Study: 10989245
Drug: Tibolone therapy
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone therapy (group T)
Study: 10989245
Drug: Continuous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous conjugated estrogen (CE) 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg (group E)
Study: 6533776
Drug: Tinidazole prophylaxis
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole prophylaxis with 8-h dosage interval (500 mg intravenous infusion)
Study: 6533776
Drug: Tinidazole prophylaxis
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole prophylaxis with 12-h dosage interval (500 mg intravenous infusion)
Study: 6533776
Drug: Tinidazole prophylaxis
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole prophylaxis (500 mg intravenous infusion)
Study: 28483191
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (control group)
Study: 25587312
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g magnesium sulfate in normal saline infused in 20 minutes on days one to three (case group)
Study: 25587312
Drug: Standard medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medications and placebo (control group)
Study: 25587312
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g magnesium sulfate in normal saline (case group)
Study: 25587312
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (case group)
Study: 22968127
Drug: Arthroscopic partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic partial meniscectomy combined with a standardized physical therapy program
Study: 22968127
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy program alone
Study: 12170856
Drug: Two-implant overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-implant overdenture on ball attachments
Study: 11158794
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (observed without therapy)
Study: 29725986
Drug: Active analgesic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active analgesic treatment (paracetamol or buprenorphine transdermal system)
Study: 16816307
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (n=21)
Study: 16816307
Drug: Brief dynamic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief dynamic therapy (n=23)
Study: 12784590
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg per kg body weight, administered over 3 days)
Study: 10791849
Drug: Chemotherapy (+)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (+) in TS-(+) group
Study: 10791849
Drug: Chemotherapy (-)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (-) in TS-(+) group
Study: 10791849
Drug: Chemotherapy (+)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (+) in TS-(‐) group
Study: 10791849
Drug: Chemotherapy (-)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (-) in TS-(‐) group
Study: 1495743
Drug: Calcitonin nasal
Normalized name: calcitonin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin nasal spray (300 MRC units)
Study: 30856378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and fluoxetine (COMB)
Study: 30856378
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) vs. Fluoxetine (FLX)
Study: 30856378
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) vs. Combination of CBT and fluoxetine (COMB)
Study: 30856378
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) vs. Combination of CBT and fluoxetine (COMB)
Study: 24515550
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist intervention involving medication reconciliation, patient education, and improved communication of the discharge medication plan.
Study: 16791807
Drug: BMC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC therapy
Study: 9854660
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 50 mg/kg
Study: 16077392
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 100 mg/kg
Study: 9854660
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 150 mg/kg
Study: 8568017
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with food (medium-fat breakfast)
Study: 8568017
Drug: Atorvastatin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin without food (fasting)
Study: 26466809
Drug: Standard intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intervention A: continuance of oral intake and regular mouth care
Study: 26466809
Drug: Standard intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intervention B: continuance of oral intake, regular mouth care and clinically assisted hydration
Study: 21385928
Drug: sulindac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulindac (300 mg daily)
Study: 21385928
Drug: etodolac (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac (400 mg daily)
Study: 18977478
Drug: Simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20mg once daily for 2 months
Study: 18977478
Drug: Pravastatin 40mg
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40mg once daily for 2 months
Study: 9380241
Drug: Active-type vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-type vitamin D3 (VD) administered to Group 2 (19 patients; 10 males and 9 females)
Study: 9380241
Drug: No active-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active-type vitamin D3 (VD) administered to Group 1 (19 patients; 15 males and 4 females)
Study: 7700068
Drug: Antihypertension therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertension therapy
Study: 29459361
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg
Study: 23391676
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 or 120 mg daily
Study: 7033016
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg daily
Study: 11158556
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions in pregnancy/perinatal medicine
Study: 11158556
Drug: Antiplatelet agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet agents for prevention of pre-eclampsia
Study: 2525996
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis)
Study: 2525996
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg BID)
Study: 28753932
Drug: Red ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red ginseng (3000 mg/day) for three months
Study: 23979005
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight gain prevention intervention (medium-intensity) including tailored behavior change goals, weekly self-monitoring via interactive voice response, monthly counseling calls, tailored skills training materials, and a gym membership.
Study: 21782874
Drug: rHPIV3cp45 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHPIV3cp45 vaccine (10^5 TCID50 dose)
Study: 19035501
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,000 mg of calcium and 400 IU of vitamin D)
Study: 16798389
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and aspirin plus bivalirudin
Study: 12672184
Drug: Ro 45‐2081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 45‐2081 (low dose 0.05 mg/kg, maximum 5 mg)
Study: 12672184
Drug: Ro 45‐2081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 45‐2081 (mid-dose 0.2 mg/kg, maximum 20 mg)